Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients

Gynecologic Oncology

Volumn 71, Issue 3, 1998, Pages 431-436

  Vergote, I ^a   De Wever, I ^a   Tjalma, W ^a   Van Gramberen, M ^a   Decloedt, J ^a   Van Dam, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; LAPAROSCOPY; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0032422162     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5213     Document Type: Article

References (34)

1. 1. Griffiths CT, Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58:131-142, 1978
2. 2. Smith JP, Day TG: Review of ovarian cancer at the University of Texas Systems Cancer Center, M. D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 135:984-990, 1979
3. 3. Bertelsen A, Jakobsen A, Andersen JE, et al.: A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 28:161-169, 1987
4. 4. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1:353-359, 1987
5. 5. Voest EE, van Houwelingen JC, Neijt JP: A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer 25:711-720, 1989
6. 6. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166:504-511, 1992
7. 7. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67:783-788, 1986
8. 8. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6:983-989, 1988
9. 9. Potter ME, Partridge EE, Hatch KD, Soong S, Austin JM, Shingleton HM: Primary surgical therapy of ovarian cancer: how much and when? Gynecol Oncol 40:195-200, 1991
10. 10. De Wever I: Surgery for Advanced Ovarian Cancer. A Critical Analysis of Its Contribution to Combined Treatment. Leuven, Belgium, Catholic University of Leuven, 1991, pp. 1-127
11. 11. Meerpohl HG, Sauerbrei W, Schumacher M, Pfleiderer A: Welche parameter beinflussen die Grosse des postoperativen Tumorrestes beim fortgeschrittenen Ovarialkarzinom. Arch Gynecol Obstet 250:174-175, 1991
12. 12. Tulusan AH, Neumann-Kleen T, Adam R, Atanasov N, Ronay G, Lang N: Morbiditat der radikalen Krebschirurgie des Ovarial-Karzinoms. Arch Gynecol Obstet 250:171-172, 1991
13. 13. Rath W, Meden H, Brill A, Kuhn W: Ergebnisse bei der operativen Primartherapie des Ovarialkarzinoms. Arch Gynecol Obstet 250:175-176, 1991
14. 14. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang H: The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 47:203-209, 1992
15. 15. Swenerton KD, Hislop TG, Spinelli J, et al: Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65:264-270, 1985
16. 16. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB: Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 4:515-523, 1986
17. 17. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987
18. 18. Hogberg T, Carstensen J, Simonsen E: Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 48:39-49, 1993
19. 19. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-980, 1994
20. 20. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413-420, 1983
21. 21. Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van Der Velde EA, Nooy M: The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 30:347-358, 1988
22. 22. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 47:159-166, 1992
23. 23. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettener H: Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103-106, 1991
24. 24. Friedlander ML, Medley DW, Swanson C, et al: Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 6:282-290, 1988
25. 25. Webb MJ: Cytoreduction in ovarian cancer: achievability and results. Balliere's Clin Obstet Gynecol 3:83-94, 1989
26. 26. Farias-Eisner R, Oliveira M, Teng F, Berek J: The influence of tumor distribution number and size after optimal primary cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 46:267, 1992
27. 27. Eisenkop SM, Nalick RH, Wang HJ, Teng NNH: Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 51:224-229, 1993
28. 28. van Dam PA, Tjalma W, Weyler J, Van Oosterom AT, Buytaert P: Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized study. Am J Obstet Gynecol 174:943-950, 1996
29. 29. Lawton FG, Redman CW, Luesley DM, Chan KK, Blacklegde G: Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 73:61-65, 1989
30. 30. Jacob JH, Gershenson DM, Morris M, Copeland L, Burke TW, Wharton JT: Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer. Gynecol Oncol 42:146-150, 1991
31. 31. Schwartz PE, Chambers JT, Makuch R: Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53:33-37, 1994
32. 32. Surwit E, Childers J, Atlas M, et al: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 6:356-361, 1996
33. 33. Nelson BE, Rosenfeld AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166-172, 1993
34. 34. van der Burg MEL, van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995